

RAPID ONSET OF ACTIVITY OF TIGILANOL TIGLATE (STELFONTA®) IN CANINE MAST CELL TUMOURS USING TIME-ASSESSED THERMOGRAPHIC IMAGES

OBJECTIVES

Clinical evaluation of tigilanol tiglate for intratumoral treatment of canine mast cell tumours (MCT) using thermography.

MATERIALS & METHODS

- **Animals**
 - 20 dogs with 21 confirmed MCTs.
- **Evaluations**
 - Thermography of the treated tumours before the treatment, during the injection, 2 hours, 4 hours, and 1, 7, 14 and 28 days after the treatment.

RESULTS

- **In the hours following treatment: tumour temperature decreased within 1 hour, changes in vascularity were apparent within 4 hours and haemorrhagic necrosis evident within 48 hours.**
- **Healthy granulation tissue developed within 10.4 days (mean). Wounds resolved in 58% of dogs by day 28.**
- **Complete response achieved in 76.2% of dogs.**
- **No significant adverse events were recorded.**

CLINICAL INTEREST

Thermographic images demonstrated the absence of residual disease in the tumour margins of dogs achieving a complete response following a tigilanol tiglate treatment.



REFERENCES

Melo S, Januario E, Pinto AC, Zanuto E, Franchini M, Ambrosio A, Matera J. Intra-Tumoral Injection of Tigilanol Tiglate in Canine Mast Cell Tumors: Time Assessed Thermographic Images, Computed Tomography and Clinical Response. In: ACVIM Forum 2019 [Internet]. 2019.